GlassScriptPhysician profile
Brent William Robinson
NPI 1568404622
$4,265.12
in general payments reported to CMS, 2019-2025
24 companies · $912 in 2025
The $912 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $269 · 2021: $422 · 2022: $635 · 2023: $626 · 2024: $785 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,040 · Travel and Lodging: $263 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,039.68 |
| Travel and Lodging | $262.85 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $625.69 | 2019-2024 | |
| Biosense Webster, INC. | $584.78 | 2023-2025 | Carto 3 |
| E.R. Squibb & Sons, L.L.C. | $386.16 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $343.61 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $321.99 | 2021-2023 | Verquvo |
| Pfizer INC. | $276.30 | 2019-2024 | |
| Intuitive Surgical, INC. | $262.85 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.85 | 2019-2024 | Jardiance |
| Motiva USA, LLC | $219.87 | 2025 | |
| Medtronic, INC. | $154.04 | 2021-2025 | Linq II, Cobalt Dr Mri Surescan, Tri-Ad |
| Amgen INC. | $146.90 | 2019-2022 | |
| Penumbra, INC. | $133.91 | 2024 | Penumbra System |
| Medtronic Vascular, INC. | $90.78 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.62 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $75.61 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $65.60 | 2019-2022 | |
| Boston Scientific Corporation | $62.11 | 2019 | |
| Sanofi-Aventis U.S. LLC | $50.51 | 2019-2024 | |
| Abiomed | $47.14 | 2021-2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2025 | |
| Allergan, INC. | $19.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.21 | 2020 | |
| Amarin Pharma, INC. | $15.68 | 2019 | |
| Gilead Sciences, INC. | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.